Brain Biotech Ag · XETR:BNN

Brain Biotech — Investor Day (December 2024)

15 slides from Brain Biotech's investor day presentation, Dec 12, 2024

  1. Slide 1: BRAIN Biotech AG – BRAIN CMD 2024, Executing Vision 100

    BRAIN Biotech AG Creating a #BiobasedFuture BRAIN CMD 2024 Michael Schneiders, CFO Executing Vision 100 Zwingenberg, December 12th, 2024 Since 2021 we have been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labor, the environm

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This document may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties, as they relate to future events and are based on current assumptions of the Company, which may not occur at all in the future or may not occur as assum

  3. Slide 3: Executing Vision 100

    Executing Vision 100 building an admired global Top 10 enzyme enterprise  Strong Revenue Growth to ‘28/29: 15% average annual product CAGR to realize Vision 100  Positive Operating Leverage: ~100 Bsp yearly adj. EBITDA margin improvement BRAINBiocatalysts  Attractive Target Markets: structural gr

  4. Slide 4: Strong Achievements Over the Last Two Years

    Strong Achievements Over the Last Two Years significantly reduced complexity and costs Minority buy-outs were prerequisite for:  efficient corporate structure  synergy harvesting and aligned performance management Simplified structure & cost savings:  reducing number of group entities from 18 to

  5. Slide 5: The New BRAIN Biotech Organization: Two Distinct Business Segments

    The New BRAIN Biotech Organization: Two Distinct Business Segments creating a high performance organization with a clear focus Creating a #BiobasedFuture BioProducts BioIncubator Enzyme products, Projects & participations microorganisms & ingredients to create highly innovative solutions Incubator R

  6. Slide 6: New Organization With High Transparency

    New Organization With High Transparency two pillar operational structure plus active holding Creating a #BiobasedFuture Holding Costs ~€ 4m BRAINBioIncubator Specialized enzyme products, microorganisms & ingredients Projects & participations with highly innovative solutions BRAINBioIncubator Pipelin

  7. Slide 7: BRAIN Biotech Group Value Creation Strategy

    BRAIN Biotech Group Value Creation Strategy all parts to strongly contribute  Active portfolio management  Facilitate cross-divisional synergies  Drive M&A  Strategic financing BRAINBioIncubator Projects & participations with highly innovative solutions Specialized enzyme products, microorganism

  8. Slide 8: Five-Year Targets: Strong Growth, Margin Increase + High BioIncubator Value Contribution

    Five-Year targets*: Strong Growth, Margin Increase + High BioIncubator Value Contribution mid-term targets updated  originally issued 02/23 as 4-6 year targets BRAINBiocatalysts  Revenues: €100 million U  Margin: adj. EBITDA margin 15% P  R&D ratio: 4-6% of group sales G R  CAPEX: average annua

  9. Slide 9: BRAINBiocatalyst Products: Double Digit Sales CAGR

    BRAINBiocatalyst Products: Double Digit Sales CAGR building a global Top 10 enzyme enterprise Specialized enzyme products, microorganisms & ingredients Indicative Sales development (in € million) In year 5 we target:  Base Business: grown organically ahead of GDP  New Products: substantially added

  10. Slide 10: BRAINBiocatalyst: Positive Operating Leverage

    BRAINBiocatalyst: Positive Operating Leverage ~100 bsp yearly adj. EBITDA margin improvement Specialized enzyme products, microorganisms & ingredients Indicative adj. EBITDA development (in € million) Drivers of adj. EBITDA improvement:  Base Business: mix improvements, procurement synergies, scale

  11. Slide 11: BioIncubator: Harvesting Past Investment & Funding the Future

    BioIncubator: Harvesting Past Investment & Funding the Future strong recent track record BRAINBioIncubator Projects & participations with highly innovative solutions Recent Transactions: Royalty Pharma / deucrictibant Up to €138 million Up to €92 million plus royalties  upfront payment of €18.41m r

  12. Slide 12: M&A: Successful Track Record of Acquisitions & Integration

    M&A: Successful Track Record of Acquisitions & Integration financial criteria and business rationale Business M&A Criteria Financial M&A criteria  B2B only  Bolt-on focus  Clearly focused on the enzyme product business  Profitability in-line with BRAINBiocatalysts or achieve this  Specialty app

  13. Slide 13: BRAIN Biotech's Business Model with Attractive Valuation Potential

    BRAIN Biotech’s Business Model with Attractive Valuation Potential integrated Bio-Solution & Bio-Products provider is a highly valued business model in equity markets High Regulatory Entry Hurdles Food & Life Science Strong Value- Specialized Added Products Products + Attractive Sustainability Margi

  14. Slide 14: Why invest in BRAIN Biotech?

    Why invest in BRAIN Biotech? five strong reasons 1. Clear strategy of profitable growth in speciality enzyme segments Our goal is to become one of the world’s top 10 enzyme companies 2. Large, growing and accessible market with excellent profitability We have excellent growth opportunities in our fo

  15. Slide 15: Thank you very much for your interest.

    Thank you very much for your interest. BRAIN Biotech AG Darmstädter Straße 34−36 64673 Zwingenberg, Germany +49 (0) 6251-9331-0 www.brain-biotech-group.com Your contacts: Michael Schneiders, CFO Martina Schuster, IR +49 (0) 6251-9331-69 [email protected] brainbiotechag BRAIN Biotech AG BRAIN Biot

BRAIN Biotech — Investor Day (December 2024) on 6ix